Biox Nexevo

Indonesia · Ingredient Compliance

The Negative List: What You Can't Formulate With

The first list every supplement brand should check — before a single dollar goes into formulation. Here's exactly what BPOM restricts, and how to screen an ingredient before you build around it.

Reviewed by Biox Nexevo Regulatory Affairs Updated 2 Sep 2026 7 min read

The screening framework

3 Lists

Positive, Negative, and the "Grey Area"

Key banned category BKO
Heavy metals tested 5
Rejection if listed Immediate
Screen My Formulation
Verified against: BPOM Decree No. 70/2025 · BPOM Reg. No. 6/2025 · pom.go.id

Indonesia maintains a negative list of ingredients restricted or prohibited in food supplements. A formulation built around a negative-list ingredient fails BPOM review regardless of how good everything else about the product is — screening at the brief stage, not after a failed audit, is what actually protects a launch timeline.

The Three-List Framework

Before diving into specifics, it helps to understand how BPOM actually categorises substances. Every ingredient a formulation brief proposes falls into one of three buckets — and which bucket determines how fast (or whether) your product can move forward.

Positive List

Pre-Approved

Vitamins, minerals, amino acids, botanicals with defined dosage limits

Negative List

Strictly Banned

BKO, narcotics, and substances with high toxicity profiles

Grey Area

Needs Assessment

On neither list — common for novel nutraceutical ingredients

Term to know — BKO

Bahan Kimia Obat — undeclared pharmaceutical chemical compounds. This is one of the most heavily enforced categories on the negative list, most commonly found as illegal adulterants in weight-management and sexual-health products. A single BKO finding results in immediate rejection.

The Risk Isn't the Obvious Cases

Almost no serious brand knowingly formulates with a banned narcotic or an undeclared drug compound. The real risk is subtler: a botanical extract permitted at one concentration but restricted above it, a heavy-metal contamination level that only surfaces in lab testing after the formulation is finalised, or a "grey area" ingredient that turns out to need a full safety dossier your timeline never accounted for.

Publicly available negative lists also aren't always the most current source — BPOM's internal review database is frequently more up to date than what's published, which means a formulation cleared against an older reference can still fail current review.

What's Actually Restricted

Five categories make up the bulk of BPOM's negative list — get familiar with the shape of it, not every entry.

Most enforced

BKO (undeclared drugs)

Pharmaceutical chemical compounds hidden in supplement formulas.

Narcotics & psychotropics

Controlled substances, outright prohibited in any formulation.

Heavy metals over limit

Lead, mercury, arsenic, cadmium and tin — tested against defined thresholds.

Ethyl alcohol >1%

Restricted above 1% content in oral liquid formulations.

Protected species

Ingredients from plants or animals under Indonesian conservation law.

Risk-assessed excipients

Substances like propylene glycol and PEG face hazard-analysis scrutiny under recent BPOM ordinances.

Common mistake

Screening a formulation against an older published negative list instead of BPOM's current active framework. Regulations update through decrees and ordinances between full list revisions — the most recent classification revision came via BPOM Decree No. 70 of 2025.

How to Check an Ingredient

Cross-reference

Against BPOM's current permitted and prohibited lists.

Confirm dosage

Maximum permitted amount if restricted-but-permitted.

Request a CoA

Heavy metal and microbial limits from the supplier.

Check novelty

Confirm if a safety dossier is needed for grey-area ingredients.

This is precisely why manufacturing through a halal-native, regulation-aware OEM partner matters — ingredient-level compliance documentation should already exist rather than being assembled from scratch for every new SKU, and every formulation brief should be screened before trials begin, not after.

How Biox Nexevo Handles This

Every brief screened before formulation trials begin.

We screen against Indonesia's negative list — and Malaysia's, Singapore's, and Vietnam's restricted-ingredient frameworks simultaneously — before a single trial starts, preventing the single most expensive reason a launch stalls: reformulating after rejection.

Frequently Asked Questions

BKO stands for Bahan Kimia Obat — undeclared pharmaceutical chemical compounds. This is one of the most heavily enforced categories on BPOM's negative list, commonly found as illegal adulterants in weight-management and sexual-health products.

A product containing any negative-list substance faces immediate rejection during BPOM review, regardless of how it's marketed internationally or how it performs in other markets.

This is the "grey area" — common with novel or cutting-edge nutraceutical ingredients. BPOM typically requires a formal safety assessment before a grey-area ingredient can be approved for use.

Not necessarily. BPOM's internal database is often more current than the publicly available lists, which is why formulation briefs should be screened directly against BPOM's active framework rather than an older published list alone.

MD (Makanan Dalam) applies to products manufactured domestically in Indonesia. ML (Makanan Luar) applies to products manufactured abroad and imported. Negative-list screening applies to both classifications.

Want your formulation screened before you commit to it?

Talk to Us on WhatsApp

Sources: BPOM (Badan Pengawas Obat dan Makanan) restricted and prohibited substance regulations for food supplements; BPOM Decree No. 70 of 2025 on revised ingredient classifications; BPOM Regulation No. 6 of 2025 on stability testing. This page is general guidance, not a substitute for formal ingredient clearance — confirm any specific ingredient's current status directly with BPOM or a qualified regulatory consultant before finalising a formulation.

Continue Your Research

Related regulatory guides